NCT02703181 - Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

September 10, 2015

Study Completion Date

September 10, 2015

Conditions

Embryo Transfer

Interventions

DRUG

Epelsiban (GSK557296)

White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.

DRUG

Placebo to match GSK557296

White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.

Trial Locations (1)

66211

GSK Investigational Site, Overland Park